| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3897 |
| Trial ID | NCT06447987 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Cetuximab |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase Ib Study to Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy in Adult Patients With Relapsed/Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia |
| Year | 2024 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 23328|NCI-2024-03338|23328|P30CA033572 |
| Cohort 1 | |||||||||
|
|||||||||